| Lyka Labs Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 500259 |
NSE Symbol : LYKALABS |
P/E(TTM) : 234.45 |
|
ISIN Demat : INE933A01014 |
Div & Yield% : 0.00 |
EPS(TTM) : 0.33 |
|
Book Value(₹) : 37.02 |
Market Cap(₹Cr) : 276.13 |
Face Value(₹) : 10.00 |
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|
| Gross Sales | 32.97 | 29.18 | 30.52 | 32.92 | 41.16 | 30.10 |
| Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Sales | 32.97 | 29.18 | 30.52 | 32.92 | 41.16 | 30.10 |
| Other Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income | 1.21 | 0.67 | 0.72 | 0.87 | 0.13 | 0.62 |
| Total Income | 34.19 | 29.84 | 31.24 | 33.80 | 41.28 | 30.72 |
| Total Expenditure | 36.12 | 25.79 | 27.11 | 27.84 | 35.82 | 26.05 |
| PBIDT | -1.94 | 4.06 | 4.13 | 5.96 | 5.47 | 4.67 |
| Interest | 0.79 | 0.85 | 0.52 | 0.62 | 0.52 | 0.65 |
| PBDT | -2.73 | 3.20 | 3.61 | 5.34 | 4.95 | 4.02 |
| Depreciation | 2.07 | 2.03 | 1.34 | 1.75 | 1.68 | 1.68 |
| Tax | 0.18 | 0.31 | 0.62 | 0.86 | 0.84 | 0.40 |
| Fringe Benefit Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | -1.35 | 0.05 | 0.35 | 0.03 | -0.05 | 0.20 |
| Reported Profit After Tax | -3.63 | 0.81 | 1.31 | 2.70 | 2.47 | 1.75 |
| Extra-ordinary Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Adjusted Profit After Extra-ordinary item | -3.63 | 0.81 | 1.31 | 2.70 | 2.47 | 1.75 |
| EPS (Unit Curr.) | -1.02 | 0.22 | 0.36 | 0.75 | 0.69 | 0.49 |
| EPS (Adj) (Unit Curr.) | -1.02 | 0.22 | 0.36 | 0.75 | 0.69 | 0.49 |
| Calculated EPS (Unit Curr.) | -1.02 | 0.23 | 0.37 | 0.76 | 0.69 | 0.49 |
| Calculated EPS (Adj) (Unit Curr.) | -1.02 | 0.23 | 0.37 | 0.76 | 0.69 | 0.49 |
| Calculated EPS (Ann.) (Unit Curr.) | -4.06 | 0.91 | 1.46 | 3.02 | 2.77 | 1.96 |
| Calculated EPS (Adj) (Ann.) (Unit Curr.) | -4.06 | 0.91 | 1.46 | 3.02 | 2.77 | 1.96 |
| Book Value (Unit Curr.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity | 35.69 | 35.69 | 35.69 | 35.69 | 35.69 | 35.69 |
| Reserve & Surplus | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Public Shareholding (No. Of Shares) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public Shareholding (% in Equity) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - No. of Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - % in Total Promoters Holding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Pledged/Encumbered - % in Total Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - No. of Shares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - % in Total Promoters Holding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Non Encumbered - % in Total Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBIDTM(%) | -5.88 | 13.91 | 13.53 | 18.10 | 13.29 | 15.51 |
| PBDTM(%) | -8.28 | 10.97 | 11.83 | 16.22 | 12.03 | 13.36 |
| PATM(%) | -11.01 | 2.78 | 4.29 | 8.20 | 6.00 | 5.81 |